Whether you're sourcing suppliers or finding providers, start your journey with confidence today.
Selank (TP-7 Heptapeptide)
Also known as: TP-7, Selanc
Confidence
Updated 2026-03-18
Selank is a synthetic heptapeptide derived from the endogenous immunomodulatory peptide tuftsin, with an added Pro-Gly-Pro sequence for stability. Developed at the Institute of Molecular Genetics (Russian Academy of Sciences), it is approved in Russia as an anxiolytic and nootropic. It exhibits both anxiolytic and cognitive-enhancing properties without sedation or addiction potential.
Class
Nootropic / Anxiolytic Peptide
Routes
Intranasal, Subcutaneous
Half-Life
~2–3 minutes (IV); intranasal delivery extends functional duration to ~2–4 hours via CNS depot effect
Selank modulates multiple neurotransmitter systems: it influences GABAergic transmission (anxiolytic effect without benzodiazepine-like sedation), modulates serotonin and dopamine metabolism, enhances BDNF expression (neuroplasticity), and stabilizes enkephalin degradation. It also retains the immunomodulatory properties of its parent peptide tuftsin, influencing IL-6 and T-cell function.
Half-Life
~2–3 minutes (IV); intranasal delivery extends functional duration to ~2–4 hours via CNS depot effect
Bioavailability
Intranasal: ~92.8% (per Russian pharmacokinetic data)
Approved (Russia): Generalized anxiety, cognitive enhancement, neurasthenia. Research: anxiety disorders, cognitive decline, PTSD, immunomodulation.
Russian clinical trials supported regulatory approval. Published studies (primarily in Russian journals) demonstrate anxiolytic effects comparable to benzodiazepines without sedation, dependence, or withdrawal. Cognitive enhancement shown in memory and attention tasks. Limited Western peer-reviewed data. No large-scale Western RCTs.
Human Studies
15
Animal Studies
50
Reported as very well-tolerated in Russian clinical data. No significant sedation, dependency, or withdrawal. Mild nasal irritation with intranasal use. No serious adverse events in published literature. Western safety data is limited.
Approved in Russia since 2009. Not FDA-approved or EMA-approved. Limited recognition in Western pharmacopeia. Available through international research peptide suppliers.
Drug Interactions: Theoretical interactions with GABAergic drugs, SSRIs, immunosuppressants. Monitoring: Anxiety symptom scales, cognitive testing, immune markers if used for immunomodulation. Research Gaps: No Western RCTs. Long-term safety data limited to Russian post-marketing surveillance. Optimal dosing for non-Russian populations not established.
Intranasal
Common Range
250–750 mcg/day
Timing
Morning and/or early afternoon
Frequency
1–3 times daily
Cycling
Russian protocols: 14-day courses, repeatable
Important Note
NOT FDA-approved. Approved in Russia as intranasal spray. Most data from Russian clinical practice.
Connect with a verified provider offering Selank therapy near you.
Nootropic / Neuroprotective Peptide
Semax is a synthetic heptapeptide analog of ACTH(4-10) developed at the Institute of Molecular Genetics in Russia. It is approved in Russia and several CIS countries as a nootropic and neuroprotective agent for stroke recovery, cognitive enhancement, and optic nerve disease. Unlike full-length ACTH, it has no corticosteroid-stimulating activity.
Nootropic / Cognitive Enhancer
Dihexa is a small peptide-derived compound developed at Washington State University that acts as a potent hepatocyte growth factor (HGF) receptor (c-Met) agonist. In preclinical studies, it demonstrated cognitive-enhancing effects up to 10 million times more potent than BDNF in promoting synaptic connectivity. It is one of the most discussed compounds in nootropic communities, though human data is essentially absent.
Nootropic / Antidepressant Peptide
PE-22-28 is a synthetic heptapeptide derived from sortilin propeptide (spadin) that acts as a specific blocker of the TREK-1 potassium channel. TREK-1 deletion in mice produces an antidepressant-resistant phenotype, making TREK-1 blockade a novel antidepressant mechanism. PE-22-28 shows rapid-onset antidepressant-like effects in animal models within 4 days — compared to 2–4 weeks for SSRIs. It is an early-stage research compound.
Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, stopping, or modifying any peptide therapy. PeptideSupplierMatch does not prescribe, sell, or distribute peptides.
Whether you're sourcing peptides for your business or looking for providers near you, we can help.